Article
Oncology
Csilla Kriston, Mark Hernadfoi, Mark Plander, Agnes Mark, Ferenc Takacs, Agnes Czeti, Gabor Szaloki, Orsolya Szabo, Andras Matolcsy, Gabor Barna
Summary: Lenalidomide has limited effect on BMSCs, increases apoptosis of CLL cells, decreases interaction with microenvironment, and enhances expression of certain cell molecules.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Fenghua Qian, Brooke E. Arner, Kathleen M. Kelly, Charyguly Annageldiyev, Arati Sharma, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Summary: Interleukin-4 (IL-4) plays a therapeutic role in acute myeloid leukemia (AML) by alleviating the severity of the disease. IL-4 enhances the expression of hematopoietic- PGD(2) synthase (H-PGDS) to increase the production of endogenous cyclopentenone prostaglandins (CyPGs), leading to apoptosis of leukemia-initiating cells (LICs).
Article
Multidisciplinary Sciences
Ningshu Lin, Luyan Chen, Yunni Zhang, Yi Yang, Lei Zhang, Lei Chen, Peng Zhang, Huiming Su, Min Yin
Summary: KIF4A overexpression is associated with bladder cancer and activation of immunocytes. High expression of KIF4A is correlated with decreased CD8(+) tumor-infiltrating lymphocytes and worse prognosis in patients. KIF4A promotes tumor growth, especially in immune-competent mice.
SCIENTIFIC REPORTS
(2022)
Review
Biochemistry & Molecular Biology
Daniela Damiani, Mario Tiribelli
Summary: The prognosis of acute myeloid leukemia (AML) is poor due to tumor cell immune escape, which weakens T-cells. Inhibiting immune checkpoints (ICs) through immune checkpoint inhibitors (ICIs) has emerged as a promising therapeutic strategy for AML. However, the results of clinical trials testing ICIs, alone or in combination with other treatments, in AML are conflicting.
Article
Immunology
Giovanna Merchand-Reyes, Ramasamy Santhanam, Frank H. Robledo-Avila, Christoph Weigel, Juan De Dios Ruiz-Rosado, Xiaokui Mo, Santiago Partida-Sanchez, Jennifer A. Woyach, Christopher C. Oakes, Susheela Tridandapani, Jonathan P. Butchar
Summary: The development of nurse-like cells (NLCs) in chronic lymphocytic leukemia (CLL) depends on MEK signaling, and inhibition of MEK can slow down CLL progression and increase survival time in vivo. Targeting the MEK/ERK pathway may be an effective treatment strategy for CLL.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Paolo Giannoni, Cecilia Marini, Giovanna Cutrona, Gian Mario Sambuceti, Franco Fais, Daniela de Totero
Summary: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. In this disease, interactions between CLL cells and bone tissue components may lead to alterations in bone homeostasis. Recent research suggests that disruption of the endosteal niche by the expansion of a leukemic B cell clone is worth further investigation for potential therapeutic approaches.
Article
Hematology
Cedric Menard, Delphine Rossille, Joelle Dulong, Tien-Tuan Nguyen, Ilenia Papa, Maelle Latour, Nadege Bescher, Isabelle Bezier, Myriam Chouteau, Thierry Fest, Roch Houot, Franck Morschhauser, Karin Tarte
Summary: The study found that lenalidomide activated T cells in patients with FL, triggering gene changes related to effector memory T cell features, which were validated at the phenotypic and functional levels. Additionally, high effector T cell and regulatory T cell percentages had a negative clinical impact before and during treatment.
Review
Oncology
Elisavet Vlachonikola, Kostas Stamatopoulos, Anastasia Chatzidimitriou
Summary: The treatment of chronic lymphocytic leukemia (CLL) is continuously evolving, with immunotherapy emerging as a therapeutic option to boost immune responses against tumors. However, not all patients benefit from this approach, partly due to dysfunctional T cells in CLL. The tumor microenvironment (TME) is also crucial in impacting immune responses and tumor growth, highlighting the importance of understanding T cell defects and finding ways to overcome them for effective immunotherapy in CLL.
Review
Oncology
Pablo Oppezzo, Marcelo Navarrete, Nicholas Chiorazzi
Summary: This review article discusses the dual role of the enzyme activation-induced cytidine deaminase (AID) in adaptive immunity and B-cell malignancies, emphasizing its pathological effects as a causative factor in leukemia and lymphomas. It summarizes the expression and function of AID in normal B lymphocytes, evaluates potential causes for AID expression in leukemic cells, and discusses its role in lymphomagenesis based on recent genomic landscape analyses of leukemia and lymphomas. The review also touches upon the correlation between AID off-target mutations and tumor-gene drivers in these cancers, and how these mutations could impact disease progression.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Stephanie Sendker, Dirk Reinhardt, Naghmeh Niktoreh
Summary: Despite progress in treating childhood AML, the risk of relapse and refractory disease remains high. Immunotherapy shows promise as an effective tool against AML, but further research and specific engineering is needed to reduce toxicity.
Article
Hematology
Mario L. Marques-Piubelli, Edwin R. Parra, Lei Feng, Luisa Solis Soto, Mariana Gallardo, Sushanth Gouni, Felipe Samaniego, Mansoor Noorani, Fredrick B. Hagemeister, Jason R. Westin, Hun Ju Lee, Maria A. Rodriguez, Sattva S. Neelapu, Jillian R. Gunther, Nathan H. Fowler, Christopher R. Flowers, Ignacio I. Wistuba, Loretta J. Nastoupil, Francisco Vega, Paolo Strati
Summary: This retrospective study analyzed the outcomes of patients with follicular lymphoma who relapsed or progressed after frontline lenalidomide and rituximab treatment. The study found that chemoimmunotherapy was an effective treatment strategy for these patients. Additionally, specific macrophage populations were significantly increased in tissue samples collected at progression.
Review
Immunology
Michela Luciano, Peter W. Krenn, Jutta Horejs-Hoeck
Summary: Acute myeloid leukemia (AML) is a heterogeneous blood cancer with complex disease characteristics and cytokine networks, making treatment challenging. The development of new targeted therapies and understanding the functions of cytokines are important for improving treatment options.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yeqin Sha, Rui Jiang, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Li Wang, Lei Fan, Hui Jin, Wei Xu, Jianyong Li, Huayuan Zhu
Summary: This study identified differentially expressed pyroptosis-related genes (PRGs) between CLL and normal B cells, and constructed a risk model with three PRG signatures that showed high efficacy in predicting overall survival and time to first treatment in CLL. Functional and pathway analysis further revealed dysregulated immune and inflammatory responses in the high-risk group, as well as decreased immune cell infiltration and activity of immune-related pathways.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Laura Patrussi, Nagaja Capitani, Cosima T. Baldari
Summary: IL-9, a soluble factor secreted by immune cells, has been found in several tumor niches, with dual roles in promoting or counteracting tumor development depending on the specific type of cancer. Recent studies implicate IL-9 in chronic lymphocytic leukemia pathogenesis, yet the molecular mechanisms remain unclear.
Article
Oncology
Frank G. Rucker, Ling Du, Tamara J. Luck, Axel Benner, Julia Krzykalla, Insa Gathmann, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Lynn Savoie, Jorge Sierra, Celine Pallaud, Miguel A. Sanz, Joop H. Jansen, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Richard A. Larson, Clara D. Bloomfield, Richard M. Stone, Hartmut Doehner, Christian Thiede, Konstanze Doehner
Summary: In AML, internal tandem duplications of the FLT3 gene are associated with poor prognosis. Specifically, insertion site in TKD1 is correlated with unfavorable prognosis, and treatment with Midostaurin does not improve this condition.
Editorial Material
Hematology
Daniel A. Arber, Robert P. Hasserjian, Attilio Orazi, Vikram Mathews, Andrew W. Roberts, Charles A. Schiffer, Anne Stidsholt Roug, Mario Cazzola, Hartmut Doehner, Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fuerstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L. Illert, Jan Duerig, Sebastian Boettcher, Carsten U. Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Doehner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Summary: Despite advances in targeted therapies, patients with high-risk chronic lymphocytic leukemia (CLL) still have inferior outcomes compared to others. The CLL2-GIVe treatment regimen, combining multiple agents, has shown good efficacy and manageable safety as a first-line treatment for high-risk CLL.
Editorial Material
Hematology
Attilio Orazi, Robert P. Hasserjian, Mario Cazzola, Hartmut Dohner, Ayalew Tefferi, Daniel A. Arber
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, Courtney D. DiNardo, Lucy A. Godley, Ilaria Iacobucci, Siddhartha Jaiswal, Luca Malcovati, Alessandro M. Vannucchi, Keyur P. Patel, Daniel A. Arber, Maria E. Arcila, Rafael Bejar, Nancy Berliner, Michael J. Borowitz, Susan Branford, Anna L. Brown, Catherine A. Cargo, Hartmut Dohner, Brunangelo Falini, Guillermo Garcia-Manero, Torsten Haferlach, Eva Hellstrom-Lindberg, Annette S. Kim, Jeffery M. Klco, Rami Komrokji, Mignon Lee-Cheun Loh, Sanam Loghavi, Charles G. Mullighan, Seishi Ogawa, Attilio Orazi, Elli Papaemmanuil, Andreas Reiter, David M. Ross, Michael Savona, Akiko Shimamura, Radek C. Skoda, Francesc Sole, Richard M. Stone, Ayalew Tefferi, Matthew J. Walter, David Wu, Benjamin L. Ebert, Mario Cazzola
Summary: Myeloid neoplasms and acute leukemias are caused by somatic gene mutations that drive the clonal expansion of hematopoietic cells. Genomic characterization plays a crucial role in diagnosis, risk assessment, and clinical decision making. Conventional cytogenetics has been the main method for genomic testing, but recent advances in sequencing technology allow for more accurate detection of somatic mutations. Whole-genome sequencing shows potential as a replacement for traditional methods in patients with myeloid neoplasms, providing rapid and comprehensive genomic profiling.
Article
Oncology
Volker Arndt, Daniela Doege, Stefan Froehling, Peter Albers, Hana Alguel, Ralf Bargou, Carsten Bokemeyer, Martin Bornhaeuser, Christian H. Brandts, Peter Brossart, Sara Yvonne Brucker, Tim H. Bruemmendorf, Hartmut Doehner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann
Summary: The capacities of German Comprehensive Cancer Centers (CCCs) in various aspects of oncology care were significantly affected during the first 2 years of the COVID-19 pandemic. Follow-up, psycho-oncologic care, and tumor surgery were particularly impacted, along with other areas of multidisciplinary oncological care. This study highlights the importance of developing strategies to prevent similar limitations in the future.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Steven H. Swerdlow, Elias Campo, Daniel A. Arber, Mario Cazzola, James R. Cook, Hartmut Doehner, Martin Dreyling, Robert P. Hasserjian, Elaine S. Jaffe, Attilio Orazi, Leticia Quintanilla-Martinez, David W. Scott, Ayalew Tefferi, Jane N. Winter, Andrew D. Zelenetz
Letter
Hematology
Andrew H. Wei, Hartmut Doehner, Hamid Sayar, Farhad Ravandi, Pau Montesinos, Herve Dombret, Dominik Selleslag, Kimmo Porkka, Jun-Ho Jang, Barry Skikne, C. L. Beach, Thomas Prebet, George Zhang, Alberto Risueno, Manuel Ugidos, Wendy L. See, Daniel Menezes, Gail J. Roboz
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Duerig, Sebastian Boettcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Doehner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Meeting Abstract
Hematology
Pascal Naef, Ramin Radpour, Carla Jaeger-Ruckstuhl, Nils Bodmer, Gabriela M. Baerlocher, Hartmut Doehner, Konstanze Doehner, Carsten Riether, Adrian Ochsenbein
Article
Oncology
Lavinia Arseni, Rakesh Sharma, Norman Mack, Deepthi Nagalla, Sibylle Ohl, Thomas Hielscher, Mahak Singhal, Robert Pilz, Hellmut Augustin, Roger Sandhoff, Christel Herold-Mende, Bjoern Tews, Peter Lichter, Martina Seiffert
Summary: A better understanding of tumor-stroma crosstalk and the role of sphingosine-1-phosphate (S1P) in mediating this crosstalk is crucial for the development of therapeutic approaches for human glioma. This study shows that higher levels of S1P result in an anti-inflammatory environment and inhibition of S1P signaling improves the anti-tumor response and overall survival in glioblastoma. These findings highlight the potential of targeting S1P as a therapeutic strategy.
Letter
Oncology
Frank Stegelmann, Lino L. Teichmann, Florian H. Heidel, Carl C. Crodel, Thomas Ernst, Sebastian Kreil, Andreas Reiter, Sara Otten, Stefanie Schauer, Ruth-Miriam Korber, Kim Kricheldorf, Susanne Isfort, Hartmut Doehner, Tim H. H. Bruemmendorf, Martin Griesshammer, Konstanze Doehner, Steffen Koschmieder
Meeting Abstract
Oncology
Rabea Mecklenbrauck, Nora Borchert, Piroska Klement, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Walter Fiedler, Juergen Krauter, Arne Trummer, Bernd Hertenstein, Andreas Voss, Michael Luebbert, Verena Gaidzik, Konstanze Doehner, Hartmut Doehner, Arnold Ganser, Felicitas Thol, Michael Heuser
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
Anne Wasserloos, Stephanie Haverkamp, Hartmut Doehner, Meinrad Beer, Ambros Beer, Miriam Kull, Wolfgang Thaiss
JOURNAL OF NUCLEAR MEDICINE
(2022)
Meeting Abstract
Oncology
Michael Pfeilstoecker, Hartmut Doehner, Andrew Wei, Gail Roboz, Pau Montesinos, Felicitas Thol, Ignazia La Torre, Barry Skikne, Wendy See-Zepeda, Manuel Ugidos, Alberto Risueno, C. L. Beach, Daniel Menezes
ONCOLOGY RESEARCH AND TREATMENT
(2022)
